A Phase I Clinical Trial of 18F-LNC1007 Injection PET/CT in Healthy Volunteers and Light Tumor Burden Patients for Evaluating Its Pharmacokinetics, Biodistribution,Dosimetry and Safety
Latest Information Update: 05 Jul 2024
At a glance
- Drugs 18F LNC1007 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Yantai LNC Biotechnology
Most Recent Events
- 05 Jul 2024 New trial record